ArticleBlood advances2025

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.

Matthew S Davids et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.